PARAGON-HF: Sacubitril/Valsartan vs Valsartan in Patients With and Without Diabetes and Heart Failure With Preserved Ejection Fraction

Source: Chronic Heart Failure Updates at ACC 2022: Important New Findings for HFrEF and HFpEF*
Download Slideset
April 2-4, 2022; Washington, DC
In patients with HFpEF, sacubitril/valsartan attenuated the rate of decline in renal outcomes similarly in patients with and without diabetes compared to valsartan alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: April 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings